2022 News
PharmedOut In the News, 2022
March 2022
March 15: The Alliance for Aging Research, a pharma-funded group, organized a protest opposing the Centers for Medicare and Medicaid Services (CMS) preliminary decision not to cover Aduhelm (aducanumab, an ineffective and dangerous drug for Alzheimer's disease) except in clinical trials. PharmedOut quickly organized a counter-protest to support CMS' evidence-based decision. See Social Security Works' coverage of our event on act.tv here.
March 10: PharmedOut's fact sheet on disease mongering was cited in a newspaper article, "Creating diseases for profit," in Free Malaysia Today.
February 2022
February 20: PharmedOut's webinar "How Pharma Grooms Patients and Patient Advocacy Groups to Sell Drugs" was covered by The Lown Institute in "How some drug companies manipulate patient advocates."
February 17: Dr. Fugh-Berman was also quoted in, "The drug industry is working hard to get this Alzheimer's drug approved. Here's why it matters." by Trudy Lieberman for the Center for Health Journalism.
February 16: Dr. Fugh-Berman was quoted in a Kaiser Health News article, "Inside the tactical tug of war over the controversial Alzheimer's drug."
February 10: Dr. Fugh-Berman was quoted in the AP article "CDC proposed softer guidance on opioid prescriptions," by Mike Stobbe. "There was nothing wrong with the original guidelines," she said.
January 2022
January 18: Dr. Fugh-Berman published the op-ed,"Adding common-sense clarity to muddled CDC guidance," in The Virginian-Pilot. This piece gives clear and concise COVID guidance.
January 16: Dave Stanke and Dr. Fugh-Berman published the op-ed, "Medicare wisely declines to pay for Alzheimer's drug," in The Detroit Free Press. They applauded the Center for Medicare and Medicaid Services decision to only cover Aduhelm and related drugs in clinical trials.